Crestor Approved as Preventative

March 2010
Pharmaceutical Representative;Mar2010, Vol. 40 Issue 3, p9
The article reports that the U.S. Food and Drug Administration has approved the drug Crestor from AstraZeneca PLC for the prevention of cardiovascular diseases.


Related Articles

  • AstraZeneca Reprimanded for Nolvadex Advertisement. Fintor, Lou // JNCI: Journal of the National Cancer Institute;3/06/2002, Vol. 94 Issue 5, p330 

    Focuses on the claim of the Food and Drug Administration (FDA) against AstraZeneca LP in relation to Nolvadex drug advertisement of the company in the U.S. Accuracy of the information in the Nolvadex advertisement; Evaluation of FDA on the efficacy of Nolvadex; Comments of AstraZeneca on the claim.

  • FDA asks AstraZeneca for more Crestor data.  // Medical Marketing & Media;Sep2002, Vol. 37 Issue 9, p38 

    Reports on the request by the U.S. Food and Drug Administration for AstraZeneca to provide more information on the cholesterol-lowering drug Crestor. Requirements of the agency before approving Crestor; Issuance by the FDA of an approval letter for the drug; Steps on gaining market approval of...

  • AstraZeneca Plc.  // MondayMorning;1/24/2011, Vol. 19 Issue 3, p16 

    The article reports on the analysis of high-dose aspirin conducted by AstraZeneca PLC. It states the U.S. Food and Drug Administration (FDA) asked AstraZeneca Plc to analyze how high-dose aspirin affects the Brilinta blood thinner. It reports that the analysis by AstraZeneca Plc show high-dose...

  • Other News To Note.  // BioWorld Today;12/9/2011, Vol. 22 Issue 237, p7 

    This section offers news briefs relating to the biopharmaceutical industry as of December 9, 2011, including the approval by the U.S. Food and Drug Administration (FDA) of the topical oxybutynin gel by Antares Pharma Inc., the agreement reached by AstraZeneca plc for the purchase of Guangdong...

  • FDA Advisers Back AstraZeneca's Heart Pill.  // BioWorld Today;8/2/2010, Vol. 21 Issue 147, p6 

    The article reports on the recommendation by an advisory panel of the U.S. Food and Drug Administration (FDA) in August 2010 of the approval of AstraZeneca plc's experimental drug Brilinta to minimize thrombotic effects in patients with acute coronary syndrome.

  • Switch, new launches to bring resurgence. JOHNSEN, MICHAEL // Drug Store News;9/16/2013, Vol. 35 Issue 9, p30 

    The article reports on the possible resurgence of over-the-counter (OTC) antacids when the U.S. Food and Drug Administration (FDA) approved the Nexium as an OTC from AstraZeneca PLC.

  • Can Brilinta bring AZ over the cliff? M. A. // Medical Marketing & Media;Sep2011, Vol. 46 Issue 9, p9 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the market of the Brilinta anti-platelet for heart attack prevention from AstraZeneca PLC.

  • FDA extends review timeline for vandetanib new drug application.  // Endocrine Today;Feb2011, Vol. 9 Issue 2, p20 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to extend the duration of AstraZeneca's review of a new drug application for vandetanib as treatment for unresectable locally advanced or metastatic medullary thyroid cancer.

  • FDA adds three months to review of Iressa. Dickinson, James D. // Medical Marketing & Media;Mar2003, Vol. 38 Issue 3, p28 

    Reports on the requirement of the U.S. Food and Drug Administration for the review of the lung cancer drug Iressa from AstraZeneca PLC. Addition of several months to review information requested of AstraZeneca; Examination of safety data; Clinical testing of Iressa.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics